---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-090683"
form_type: "8-K"
ticker: "RBOT"
cik: "0001812173"
company_name: "Vicarious Surgical Inc."
filed_at: "2025-09-23T23:59:59+00:00"
generated_at: "2026-05-17T05:53:50.510773+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vicarious Surgical completes controlled builds; on track for production-equivalent system by mid-2026

## Summary
- Controlled builds completed in April and August 2025 under full QMS, demonstrating reproducibility and scalability.
- System functionality increased from 49% (June) to 63% (Sept 2025); on path to 100% by mid-2026.
- Launch indication is ventral hernia repair; 66% of US ventral hernias are still performed open (Fry et al. 2024).
- Targeting clinical readiness by year-end 2026 and human clinical trials in 2027 to support De Novo submission.
- IP portfolio includes 160 patents (50 granted/allowed, 110 pending) covering core innovations.

## SEC filing metadata
- accession: 0001213900-25-090683
- form_type: 8-K
- ticker: RBOT
- cik: 0001812173
- company_name: Vicarious Surgical Inc.
- filed_at: 2025-09-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1812173/000121390025090683/0001213900-25-090683-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1812173/000121390025090683/ea0258510-8k_vicarious.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-090683
- JSON: https://secwatch.observer/filing/0001213900-25-090683.json
- Plain text: https://secwatch.observer/filing/0001213900-25-090683.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.